【摘要】 美国国家综合癌症网络（National Comprehensive Cancer Network,NCCN）是由美国32家顶尖癌症中心组成的非盈利联盟组织，致力于改善和促进高效和优质的癌症医疗服务。作为全世界范围内最权威的癌症研究机构之一，NCCN每年定期更新发布临床实践指南，旨在提供注重实证和讲求共识的癌症管理方案。该指南是目前癌症管理中临床指导和政策的公认标准，也是医学领域最全面、最常更新的临床实践指南。目前2023年《NCCN恶性骨肿瘤临床实践指南》已更新至第2版，其较2022年第2版主要在骨巨细胞瘤、骨肉瘤、尤文肉瘤、高肿瘤突变负荷患者的药物治疗及恶性骨肿瘤的放疗原则等方面进行了更新，本文就新版指南的更新内容进行逐一解读。更多还原

【Abstract】 The National Comprehensive Cancer Network(NCCN) is a non-profit alliance of 32 top cancer centers in the United States,which is committed to improving and promoting efficient and high-quality cancer care services. As one of the most authoritative cancer research institutions in the world, the NCCN regularly updates its clinical practice guidelines every year to provide evidence-based and consensus-based cancer management solutions. NCCN guidelines are not only the consensus standards for clinical decision-making in the field of cancer but also the most comprehensive and frequently updated clinical practice guidelines in the field of medicine. The 2023NCCN Clinical Practice Guidelines for Bone Cancer has been updated to version 2. 2023. Compared with version 2. 2022, the updated content of this version mainly focused on the drug treatment of giant cell tumor of bone, osteosarcoma, Ewing’s sarcoma, and patients with high tumor mutation burden, and the principles of radiotherapy of bone cancer. This article interprets the updated content of the new version of the guidelines.更多还原